Lundbeck has announced that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development (R&D), will retire after 19 years with the company.

Gersel Pedersen joined Lundbeck in 2000 as Vice President of International Clinical Research. He was later appointed Executive Vice President of Drug Development and in 2011 appointed responsible for all Research & Development activities at Lundbeck. He is a member of the European Society of Medical Oncology, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology, the Danish Society of Clinical Oncology and the Danish Society of Internal Medicine. He also serves on the Board of Directors at Bavarian Nordic A/S (Deputy Chairman), Hansa Medical AB and Genmab A/S.

“I am proud of all we have achieved together”

“After 19 years at Lundbeck and seven years as Head of R&D I have decided to retire, even though I know that I will miss working with a great leadership team and committed and competent employees,” said Anders Gersel Pedersen. “It has been an honor to lead the R&D organization and our dedicated team of employees to advance the treatment of patients suffering from CNS disorders. I am proud of all we have achieved together.”

Lundbeck has initiated a comprehensive international search to identify the company’s next EVP, Head of R&D.

“Throughout his tenure at Lundbeck, Anders has strived to transform Lundbeck’s R&D into an organization with the potential to be one of the best within CNS disorders,” said Deborah Dunsire, President and Chief Executive Officer of Lundbeck. “I thank Anders for his leadership, innovation and dedication to Lundbeck over the past two decades and wish him all the best for the future.”

Anders Gersel’s retirement will be effective as of 31 December 2018.